Pharmaceutical Technologist - November 2007 - (Page 20) The holy grail of start-up biotech An effective electronic document management system can significantly increase a company’s purchase value. Warren Perry In the world of start-up biotech, the goal is to find the next breakthrough drug and then prepare for its commercialization and eventual purchase. When publishing a dossier, many life sciences companies struggle to efficiently compile supporting controlled documents. This is usually the result of having multiple formats and sources to compile that have been captured from a variety of paper and electronic documents, legacy versions and compounded by incomplete or inaccurate data from the outset. To address this, life sciences companies have turned to electronic document management, at the front-end and throughout the entire document life cycle, to enable a smoother and more cost-effective submission process. For a start-up biotech company the way that data is captured is as important as the data itself to a potential buyer. Capturing ‘intellectual value’ The ‘holy grail’ for many start-up biotech companies is to bring a product to clinical trials as quickly as possible, capture and publish the results, and then implement an exit strategy to be bought. The only ‘real’ property that start-up companies possess is intellectual, but many companies are realizing that their research is a lot more valuable than originally thought. Maintaining the data in a controlled electronic repository can significantly increase a company’s purchase value because the data is more up-to-date, readily accessible and more comprehensive in the event of an audit. A potential buyer is more likely to be confident that the proper data has been captured, and that there is no missing content or surprises. In this way, a sound electronic compliant document management system becomes critical to the potential acquirer. Document management is nothing new to professionals in the life sciences industry. Long before FDA, EMEA (or any other European 20 November2007 l pharmaceutical technologist
Table of Contents Feed for the Digital Edition of Pharmaceutical Technologist - November 2007 Pharmaceutical Technologist Contents Editor's Comment News Morpheus Feeling the Pressure Legal Crusaders The Holy-Grail of Start-Up Biotech Special Feature Q&A Pharmaceutical Technologist - November 2007 Pharmaceutical Technologist - November 2007 - Pharmaceutical Technologist (Page 1) Pharmaceutical Technologist - November 2007 - Pharmaceutical Technologist (Page 2) Pharmaceutical Technologist - November 2007 - Contents (Page 3) Pharmaceutical Technologist - November 2007 - Editor's Comment (Page 4) Pharmaceutical Technologist - November 2007 - Editor's Comment (Page 5) Pharmaceutical Technologist - November 2007 - Editor's Comment (Page 6) Pharmaceutical Technologist - November 2007 - Editor's Comment (Page 7) Pharmaceutical Technologist - November 2007 - News (Page 8) Pharmaceutical Technologist - November 2007 - News (Page 9) Pharmaceutical Technologist - November 2007 - Morpheus (Page 10) Pharmaceutical Technologist - November 2007 - Morpheus (Page 11) Pharmaceutical Technologist - November 2007 - Feeling the Pressure (Page 12) Pharmaceutical Technologist - November 2007 - Feeling the Pressure (Page 13) Pharmaceutical Technologist - November 2007 - Feeling the Pressure (Page 14) Pharmaceutical Technologist - November 2007 - Feeling the Pressure (Page 15) Pharmaceutical Technologist - November 2007 - Feeling the Pressure (Page 16) Pharmaceutical Technologist - November 2007 - Legal Crusaders (Page 17) Pharmaceutical Technologist - November 2007 - Legal Crusaders (Page 18) Pharmaceutical Technologist - November 2007 - Legal Crusaders (Page 19) Pharmaceutical Technologist - November 2007 - The Holy-Grail of Start-Up Biotech (Page 20) Pharmaceutical Technologist - November 2007 - The Holy-Grail of Start-Up Biotech (Page 21) Pharmaceutical Technologist - November 2007 - The Holy-Grail of Start-Up Biotech (Page 22) Pharmaceutical Technologist - November 2007 - Special Feature (Page 23) Pharmaceutical Technologist - November 2007 - Special Feature (Page 24) Pharmaceutical Technologist - November 2007 - Special Feature (Page 25) Pharmaceutical Technologist - November 2007 - Special Feature (Page 26) Pharmaceutical Technologist - November 2007 - Special Feature (Page 27) Pharmaceutical Technologist - November 2007 - Special Feature (Page 28) Pharmaceutical Technologist - November 2007 - Special Feature (Page 29) Pharmaceutical Technologist - November 2007 - Special Feature (Page 30) Pharmaceutical Technologist - November 2007 - Special Feature (Page 31) Pharmaceutical Technologist - November 2007 - Special Feature (Page 32) Pharmaceutical Technologist - November 2007 - Special Feature (Page 33) Pharmaceutical Technologist - November 2007 - Special Feature (Page 34) Pharmaceutical Technologist - November 2007 - Special Feature (Page 35) Pharmaceutical Technologist - November 2007 - Special Feature (Page 36) Pharmaceutical Technologist - November 2007 - Special Feature (Page 37) Pharmaceutical Technologist - November 2007 - Special Feature (Page 38) Pharmaceutical Technologist - November 2007 - Special Feature (Page 39) Pharmaceutical Technologist - November 2007 - Special Feature (Page 40) Pharmaceutical Technologist - November 2007 - Special Feature (Page 41) Pharmaceutical Technologist - November 2007 - Q&A (Page 42) Pharmaceutical Technologist - November 2007 - Q&A (Page 43)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.